|
1
|
Ferlay J, Shin H, Bray F, et al: GLOBOCAN
2008 v1.2, Cancer Incidence and Mortality Worldwide. IARC
CancerBase No. 10. [Internet]. International Agency for Research on
Cancer; Lyon, France: 2010, http://globocan.iarc.fruri.
Accessed October 7, 2012
|
|
2
|
Olayioye MA, Neve RM, Lane HA and Hynes
NE: The ErbB signalling network: receptor heterodimerisation in
development and cancer. EMBO J. 19:3159–3167. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Smith I, Procter M, Dowsett M, et al; HERA
study team. 2-year follow-up of trastuzumab after adjuvant
chemotherapy in HER2-positive breast cancer: a randomised
controlled trial. Lancet. 369:29–36. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Slamon DJ, Leyland-Jones B, Shak S, et al:
Use of chemotherapy plus a monoclonal antibody against HER2 for
metastatic breast cancer that overexpresses HER2. N Engl J Med.
344:783–792. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bernhard H1, Salazar L, Schiffman K, et
al: Vaccination against the HER-2/neu oncogenic protein. Endocr
Relat Cancer. 9:33–44. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Chen J, Li DS, Yu YH, et al: Clinical
significance of Her-2 protein expression in gastric cancer. Shi Jie
Hua Ren Xiao Hua Za Zhi. 18:1375–1379. 2010.(In Chinese).
|
|
7
|
Ford R, Schwartz L, Dancey J, et al:
Lessons learned from independent central review. Eur J Cancer.
45:268–274. 2009. View Article : Google Scholar
|
|
8
|
Takahari D, Yamada Y, Okita NT, et al:
Relationships of insulin-like growth factor-1 receptor and
epidermal growth factor receptor expression to clinical outcomes in
patients with colorectal cancer. Oncology. 76:42–48. 2009.
View Article : Google Scholar
|
|
9
|
Lim SW, Kim HR, Kim HY, et al:
Over-expression of Her-2 in colorectal cancer tissue, but not in
serum, constitutes an independent worse prognostic factor. Cell
Oncol (Dordr). 36:311–321. 2013. View Article : Google Scholar
|
|
10
|
Park DI, Kang MS, Oh SJ, et al: HER-2/neu
overexpression is an independent prognostic factor in colorectal
cancer. Int J Colorectal Dis. 22:491–497. 2007. View Article : Google Scholar
|
|
11
|
Demirbaş S, Sücüllü I, Yildirim S and
Celenk T: Influence of the c-erb B-2, nm23, bcl-2 and p53 protein
markers on colorectal cancer. Turk J Gastroentrol. 17:13–19.
2006.
|
|
12
|
Kavanagh DO, Chambers G, O’Grady L, et al:
Is overexpression of HER-2 a predictor of prognosis in colorectal
cancer? BMC Cancer. 9:12009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ismail HM, El-Baradie M, Moneer M, et al:
Clinico-pathological and prognostic significance of p53, Bcl-2 and
Her-2/neu protein markers in colorectal cancer using tissue
microarray. J Egypt Natl Canc Inst. 19:3–14. 2007.
|
|
14
|
Rossi HA, Liu Q, Banner B, et al: The
prognostic value of invariant chain (Ii) and Her-2/neu expression
in curatively resected colorectal cancer. Cancer J. 8:268–275.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Essapen S, Thomas H, Green M, et al: The
expression and prognostic significance of HER-2 in colorectal
cancer and its relationship with clinicopathological parameters.
Int J Oncol. 24:241–248. 2004.PubMed/NCBI
|
|
16
|
Antonacopoulou AG, Tsamandas AC, Petsas T,
et al: EGFR, HER-2 and COX-2 levels in colorectal cancer.
Histopathology. 53:698–706. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ramanathan RK, Hwang JJ, Zamboni WC, et
al: Low overexpression of HER-2/neu in advanced colorectal cancer
limits the usefulness of trastuzumab (Herceptin) and irinotecan as
therapy. A phase II trial. Cancer Invest. 22:858–865. 2004.
View Article : Google Scholar
|
|
18
|
Kapitanović S, Radosević S, Kapitanović M,
et al: The expression of p185(HER-2/neu) correlates with the stage
of disease and survival in colorectal cancer. Gastroenterology.
112:1103–1013. 1997. View Article : Google Scholar
|
|
19
|
Half E, Broaddus R, Danenberg KD, et al:
HER-2 receptor expression, localization, and activation in
colorectal cancer cell lines and human tumors. Int J Cancer.
108:540–548. 2004. View Article : Google Scholar
|
|
20
|
Kruszewski WJ, Rzepko R, Ciesielski M, et
al: Expression of HER-2 in colorectal cancer does not correlate
with prognosis. Dis Markers. 29:207–212. 2010. View Article : Google Scholar
|
|
21
|
Kountourakis P, Pavlakis K, Psyrri A, et
al: Clinicopathologic significance of EGFR and Her-2/neu in
colorectal adenocarcinomas. Cancer J. 12:229–236. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schuell B, Gruenberger T, Scheithauer W,
et al: HER 2/neu protein expression in colorectal cancer. BMC
Cancer. 6:1232006. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kim JY, Lim SJ and Park K:
Cyclooxygenase-2 and c-erbB-2 expression in colorectal carcinoma
assessed using tissue microarray. Appl Immunohistochem Mol Morphol.
12:67–70. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Marx AH, Burandt EC, Choschzick M, et al:
Heterogenous high-level HER-2 amplification in a small subset of
colorectal cancers. Hum Pathol. 41:1577–1585. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Herreros-Villanueva M, Rodrigo M, Claver
M, et al: KRAS, BRAF, EGFR and HER2 gene status in a Spanish
population of colorectal cancer. Mol Biol Rep. 38:1315–1320. 2011.
View Article : Google Scholar
|
|
26
|
Pappas A, Lagoudianakis E, Seretis C, et
al: Clinical role of HER-2/neu expression in colorectal cancer. J
BUON. 18:98–104. 2013.PubMed/NCBI
|
|
27
|
Li Q, Wang D, Li J and Chen P:
Clinicopathological and prognostic significance of HER-2/neu and
VEGF expression in colon carcinomas. BMC Cancer. 11:2772011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Seo AN, Kwak Y, Kim DW, et al: HER2 Status
in colorectal cancer: its clinical significance and the
relationship between HER2 gene amplification and expression. PLoS
One. 9:e985282014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Sobin LH and Fleming ID: TNM
classification of malignant tumors, fifth edition (1997). Union
Internationale Contre le Cancer and the American Joint Committee on
Cancer. Cancer. 80:1803–1804. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Hamtilon SR and Aaltonen LA: World Health
Organization classification of tumours. Tumours of the oesophagus.
Pathology and genetics tumors of the digestive system. IARC Press;
Lyon: 2006
|
|
31
|
Hofmann M, Stoss O, Shi D, et al:
Assessment of a HER2 scoring system for gastric cancer: results
from a validation study. Histopathology. 52:797–805. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Pauletti G, Dandekar S, Rong H, et al:
Assessment of methods for tissue-based detection of the HER-2/neu
alteration in human breast cancer: a direct comparison of
fluorescence in situ hybridization and immunohistochemistry. J Clin
Oncol. 18:3651–3664. 2000.PubMed/NCBI
|
|
33
|
Tavangar SM, Shariftabrizi A and Soroush
AR: Her-2/neu over-expression correlates with more advanced disease
in Iranian colorectal cancer patients. Med Sci Monit.
11:CR123–CR126. 2005.PubMed/NCBI
|
|
34
|
McKay JA, Loane JF, Ross VG, et al:
c-erbB-2 is not a major factor in the development of colorectal
cancer. Br J Cancer. 86:568–573. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mann M, Sheng H, Shao J, et al: Targeting
cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal
carcinoma growth. Gastroenterology. 120:1713–1719. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Pohl M, Stricker I, Schoeneck A, et al:
Antitumor activity of the HER2 dimerization inhibitor pertuzumab on
human colon cancer cells in vitro and in vivo. J Cancer Res Clin
Oncol. 135:1377–1386. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Liu W, Zhong S, Chen J and Yu Y: HER-2/neu
overexpression is an independent prognostic factor for
intestinal-type and early-stage gastric cancer patients. J Clin
Gastroenterol. 46:e31–e37. 2012. View Article : Google Scholar
|
|
38
|
Rossi E, Ubiali A, Cadei M, et al:
HER-2/neu in breast cancer: a comparative study between histology,
immunohistochemistry, and molecular technique (FISH). Appl
Immunohistochem Mol Morphol. 14:127–131. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chibon F, de Mascarel I, Sierankowski G,
et al: Prediction of HER2 gene status in HER2 2+ invasive breast
cancer: a study of 108 cases comparing ASCO/CAP and FDA
recommendations. Mod Pathol. 22:403–409. 2009. View Article : Google Scholar
|
|
40
|
Bartlett JM, Going JJ, Mallon EA, et al:
Evaluating HER2 amplification and overexpression in breast cancer.
J Pathol. 195:422–428. 2001. View
Article : Google Scholar : PubMed/NCBI
|
|
41
|
Downs-Kelly E, Yoder BJ, Stoler M, et al:
The influence of polysomy 17 on HER2 gene and protein expression in
adenocarcinoma of the breast: a fluorescent in situ hybridization,
immunohistochemical, and isotopic mRNA in situ hybridization study.
Am J Surg Pathol. 29:1221–1227. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dal Lago L, Durbecq V, Desmedt C, et al:
Correction for chromosome-17 is critical for the determination of
true Her-2/neu gene amplification status in breast cancer. Mol
Cancer Ther. 5:2572–2579. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Winston JS, Ramanaryanan J and Levine E:
HER-2/neu evaluation in breast cancer are we there yet? Am J Clin
Pathol. 121(Suppl): S33–S49. 2004.PubMed/NCBI
|
|
44
|
Seidal T, Balaton AJ and Battifora H:
Interpretation and quantification of immunostains. Am J Surg
Pathol. 25:1204–1207. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Amado RG, Wolf M, Peeters M, et al:
Wild-type KRAS is required for panitumumab efficacy in patients
with metastatic colorectal cancer. J Clin Oncol. 26:1626–1634.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Di Nicolantonio F, Martini M, Molinari F,
Sartore-Bianchi A, et al: Wild-type BRAF is required for response
to panitumumab or cetuximab in metastatic colorectal cancer. J Clin
Oncol. 26:5705–5712. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Liu W, Wang L, Yu YH, et al: Detection of
k-ras gene mutations in Chinese patients with colorectal cancer.
World Chinese Journal of Digestology. 19:1367–1374. 2011.
|
|
48
|
LaBonte MJ, Wilson PM, Fazzone W, et al:
The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the
antitumor activity of the histone deacetylase inhibitor
panobinostat in colorectal cancer models. Cancer Res. 71:3635–3648.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chen J, Li Q, Wang C, Wu J and Zhao G:
Prognostic significance of c-erbB-2 and vascular endothelial growth
factor in colorectal liver metastases. Ann Surg Oncol.
17:1555–1563. 2010. View Article : Google Scholar : PubMed/NCBI
|
